Results 171 to 180 of about 151,900 (300)

Changes in the transcriptome and synthetic lethal dependencies following <i>KRAS</i> mutant expression reveal profound tissue specificity. [PDF]

Proc Natl Acad Sci U S A
Martin TD, Choi MY, McBride JC, Elledge SJ.   +3 more
europepmc   +1 more source

Flywheel piezoelectric actuator for active vibration control applications

, 2018
Paolo Gardonio, Aleksander Kras
core   +1 more source

Flywheel proof mass actuator for velocity feedback control

, 2016
Kras, A, GARDONIO, Paolo
core   +1 more source

Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. [PDF]

Sci Adv
Zhang X, Hao Q, Yang W, Yu Y, Yan Q, Wu Z, Hu Z, Zhou X, Wang J.   +8 more
europepmc   +1 more source

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them. [PDF]

Cancer Drug Resist
Pagano Mariano M, Sgarilli E, Mijnlieff D, Visuvasam B, Blesio A, Digiacomo G, Cavazzoni A, Ferracin M, Giovannetti E.   +8 more
europepmc   +1 more source

Clinical Relevance of BACH1 Expression in Non–Small Cell Lung Cancer

International Journal of Cancer, EarlyView.
ABSTRACT BTB and CNC homolog 1 (BACH1) is a redox‐sensitive transcription factor implicated in tumor progression, metabolic reprogramming, and therapy resistance in several cancers. However, its prognostic significance and role in therapy resistance in non–small cell lung cancer (NSCLC) remain unclear.
Jing Liu, Marc A. Schneider, Julia Held, Sabine Wrenger, Wenzhang Si, Michael Allgaeuer, Florian Eichhorn, Sabina Janciauskiene   +7 more
wiley   +1 more source

Real-World Treatment Patterns and Clinical Outcomes After First-Line Therapy in Patients with KRAS G12C-Mutant Advanced Non-Small-Cell Lung Cancer in the United States. [PDF]

Cancers (Basel)
Sheffield KM, Puri T, Thoele K, Karu H, Mansharamani A, Uprety D.   +5 more
europepmc   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target. [PDF]

Curr Oncol
Iftikhar S, Xiao AH, Jin Z, Aly EH.
europepmc   +1 more source